You bring up an interesting point regarding the potential connection between semaglutide, the active ingredient in Ozempic, and reduced Alzheimer's risk. However, it's essential to critically evaluate the study you referenced. While a 40% to 70% reduction in risk sounds promising, it's crucial to consider the study's design, sample size, and whether it has been peer-reviewed. For example, was this a randomized controlled trial, or an observational study? These factors significantly affect the validity of the findings.